Patrys Limited (ASX: PAB), based in Melbourne, Australia, is a healthcare sector company focused on the development of therapeutic antibodies to treat a range of cancers and their subtypes. Some of its products in the pipeline and at different stages of development includes of the following:
Source: Company’s Website
On 30 May 2019, the company announced the new pre-clinical animal data for its lead candidate, PAT-DX1. As per the information provided, the study results confirm that Patrys’ lead agent, PAT-DX1 has the potential to suppress and control the growth of tumor in patients suffering from triple negative breast cancer (TNBC) brain metastases.
Dr James Hansen and Dr Jiangbing Zhou of the Yale School of Medicine conducted the new pre-clinical study whereby the agent PAT-DX1 was administered for 1 weekly cycle involving 3 doses, as compared to the precursor study with four weekly cycles and 12 doses in total. The study has, in fact, widened the scope of dosing as well as the impact of PAT-DX1 on TNBC brain metastases.
The study involved three broad agendas- to compare the effects of- PAT-DX1 alone, of low dose radiation alone and lastly the impact of the combination of PAT-DX1 and low dose radiation.
The observations can be summarised in the pointers mentioned below:
- PAT-DX1 agent could move past the blood-brain barrier with no associated toxicity reported.
- The separate impacts of PAT-DX1 and low dose radiation treatment were quite similar.
- The combination of the two treatments led to a significantly stronger suppression of tumor than each of the treatment alone.
This recent study further builds on the inferences of a precursor study that was undertaken last year in 2018 (results disclosed in Dec’18). In the precursor study, it was observed that if PAT-DX1 was administered in a systematic format, it could largely hamper the propagation of tumor and therefore ensure survival.
Furthermore, the new study is in line with Patrys’ long-term program to identify and optimize dosing regimens for future studies. Besides, the company in collaboration with the Yale School of Medicine is planning more studies to explore different interactions between radiations and PAT-DX1 dosing regimens. Such an initiative would contribute in the clinical development of PAT-DX1.
Breast cancer is known to be one of the leading causes of cancer deaths in women, and ~1.67 million new cases are detected each year globally. TNBC is one of the most challenging and difficult to treat subtype of breast cancer. It accounts for almost 15% -20% of all breast cancer cases.
According to the company, the global market for TNBC stood at ~USD 296 million in 2015, and by 2025, this figure is expected to reach a further high of USD 1.59 billion. Also, there is a massive unmet global medical requirement for new therapeutic innovations for targeting treatment and mitigating the devastating effects of TNBC brain metastases.
With a market capitalisation of around AU$ 28.96 million and ~ 1.07 billion outstanding shares, the PAB stock last traded at AU$ 0.029, zooming up by 07.407% (as on 30 May 2019).
This website is a service of Kalkine Media Pty. Ltd. A.C.N. 629 651 672. The website has been prepared for informational purposes only and is not intended to be used as a complete source of information on any particular company. Kalkine Media does not in any way endorse or recommend individuals, products or services that may be discussed on this site. Our publications are NOT a solicitation or recommendation to buy, sell or hold. We are neither licensed nor qualified to provide investment advice.